Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.56 |
| ▸ | RHEB | Q15382 | 9/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | DHPS | P49366 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540332 | 0.75 | PIK3CD (0.64) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL28872529 | 0.74 | RHEB (0.76) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL879761 | 0.73 | AHR (0.58) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL3335002 | 0.73 | AHR (0.58) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL9871918 | 0.73 | MAPK14 (0.49) | AHRRHEBMAPK1DHPS | |
| SCHEMBL26495 | 0.71 | AHR (0.56) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL65514 | 0.71 | AHR (0.56) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL10718362 | 0.71 | AHR (0.56) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL317600 | 0.71 | AHR (0.56) | AHRRHEBPIK3CDHTR6MAPK1 | |
| SCHEMBL113992 | 0.71 | AHR (0.56) | AHRRHEBPIK3CDHTR6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113372334-A | 2- (4-methionyl) anilino-4-amino-5-trifluoromethylpyrimidine derivatives and application thereof | 贵州医科大学 | 2021-09-10 | — | — | CN | claimed |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | claimed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | claimed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-RE43098-E1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | claimed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | claimed |
| EP-2277877-A1 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-26 | — | — | EP | claimed |
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | claimed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| US-20020091130-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | claimed |
| WO-2002036587-A2 | PROCESS FOR THE PRODUCTION OF 4-QUINAZOLINYLPIPERAZIN-1-CARBOXYLIC ACID PHENYLAMIDES | COR THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016361-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016351-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999051598-A1 | SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES: SELECTIVE NEUROPEPTIDE y RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | AHR 58/4885RHEB 4687/4885PIK3CD 4375/4885 |
| US-20020091130-A1 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | NME1, NME2, TNNI3K | AHR 3059/4885RHEB 767/4885PIK3CD 86/4885 |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | AHR 4106/4885RHEB 927/4885PIK3CD 85/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | AHR 4106/4885RHEB 927/4885PIK3CD 85/4885 |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | AHR 4106/4885RHEB 927/4885PIK3CD 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.